XPOVIO®

Dec 29, 2021View PDF

XPOVIO® (希维奥®, selinexor, ATG-010) is a highly potent and a first-in-class, oral selective inhibitor of nuclear export (SINE) compound.

In July 2021, XPOVIO® was approved by the South Korean Ministry of Food and Drug Safety (MFDS), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory); and as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two prior lines of treatment.

In July 2021, XPOVIO® was approved via a priority review process by the South Korean Ministry of Food and Drug Safety (MFDS), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory); and as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two prior lines of treatment.

Antengene has exclusive development and commercialization rights to XPOVIO in certain Asia Pacific markets including greater China.

For Medical inquiries about XPOVIO® (Selinexor), please contact: medinfo@antengene.com 

For Adverse Event inquiries, please contact: ae@antengene.com